Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, March 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 279 articles:
HTML format


 

Single Articles

  1. LI C, Wang Z, Feng N, Dong J, et al
    [Retracted] Human HLA?F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer.
    Mol Med Rep. 2024;29:63.
    PubMed    
    Abstract available

  2. WU Y, Gu X, Chen X, Cui Y, et al
    Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery.
    J Mater Chem B. 2024 Mar 1. doi: 10.1039/d3tb02837.
    PubMed    
    Abstract available

  3. HOU DY, Zhang NY, Wang L, Lv MY, et al
    Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer.
    Natl Sci Rev. 2024;11:nwae028.
    PubMed    
    Abstract available

  4. ZHONG L, Wang F
    Comparative analysis of wound healing techniques in postoperative bladder cancer patients.
    Int Wound J. 2024;21:e14820.
    PubMed    
    Abstract available

  5. QIN F, Wu J
    Impact of sarcopenia on outcomes of bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis.
    Scott Med J. 2024 Feb 29:369330241234690. doi: 10.1177/00369330241234690.
    PubMed    
    Abstract available

  6. CHIEN TM, Yang CW, Yen CH, Yeh BW, et al
    Excavatolide C/cisplatin combination induces antiproliferation and drives apoptosis and DNA damage in bladder cancer cells.
    Arch Toxicol. 2024 Feb 29. doi: 10.1007/s00204-024-03699.
    PubMed    
    Abstract available

  7. ZHANG R, Jiang W, Wang G, Zhang Y, et al
    Parkin inhibits proliferation and migration of bladder cancer via ubiquitinating Catalase.
    Commun Biol. 2024;7:245.
    PubMed    
    Abstract available

  8. MUHUITIJIANG B, Zhou J, Zhou R, Zhang Z, et al
    Development and experimental validation of an M2 macrophage and platelet-associated gene signature to predict prognosis and immunotherapy sensitivity in bladder cancer.
    Cancer Sci. 2024 Feb 29. doi: 10.1111/cas.16113.
    PubMed    
    Abstract available

  9. SONG Y, Xu T
    Neoadjuvant combination therapy (immunotherapy and chemotherapy) and treatment-related biomarkers in upper tract urothelial carcinoma.
    World J Urol. 2024;42:110.
    PubMed    


  10. BAHLBURG H, Tully KH, Bach P, Butea-Bocu MC, et al
    Improvements in urinary symptoms, health-related quality of life, and psychosocial distress in the early recovery period after radical cystectomy and urinary diversion in 842 German bladder cancer patients: data from uro-oncological rehabilitation.
    World J Urol. 2024;42:111.
    PubMed    
    Abstract available

  11. QIU X, Jiang Z, Luo Y, Tian D, et al
    PPP3CB Inhibits Cell Proliferation and the Warburg Effect in Bladder Cancer by Blocking PDHK1.
    Front Biosci (Landmark Ed). 2024;29:48.
    PubMed    
    Abstract available

  12. WESOLOW JT
    Ogilvie's Syndrome in a Male With Bladder Cancer.
    Cureus. 2024;16:e55097.
    PubMed    
    Abstract available

  13. HUANG Y, Chen Z, Shen G, Fang S, et al
    Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.
    Hum Vaccin Immunother. 2024;20:2318815.
    PubMed    
    Abstract available

  14. AKAGI N, Kanematsu A, Shigesaka K, Shimatani K, et al
    Prostate Biopsy May Not Be Indicated Early after Bacillus Calmette Guerin Treatment.
    Acta Med Okayama. 2024;78:9-13.
    PubMed    
    Abstract available

  15. ZHOU Z, Zou L, Guan Y, Jiang L, et al
    Survivin as a potential biomarker in the diagnosis of bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2024 Feb 27:S1078-1439(24)00019.
    PubMed    
    Abstract available

  16. MINATO A, Murooka K, Okumura Y, Takaba T, et al
    Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
    In Vivo. 2024;38:873-880.
    PubMed    
    Abstract available

  17. FAN J, Chen B, Luo Q, Li J, et al
    Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer.
    Biomed Pharmacother. 2024;173:116312.
    PubMed    
    Abstract available

  18. BUONERBA C, Ingenito C, Di Trolio R, Cappuccio F, et al
    Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.
    Oncol Ther. 2024 Feb 28. doi: 10.1007/s40487-024-00266.
    PubMed    
    Abstract available

  19. ELSAYED AM, Mahmoud EI, Salem MM, Khairy RA, et al
    Immunohistochemical Expression of Claudin-1 and Claudin-4 in Urothelial Carcinoma of the Urinary Bladder.
    Asian Pac J Cancer Prev. 2024;25:637-646.
    PubMed    
    Abstract available


  20. LncRNA HCP5 Promotes Cell Invasion and Migration by Sponging miR-29b-3p in Human Bladder Cancer [Retraction].
    Onco Targets Ther. 2024;17:159-160.
    PubMed    
    Abstract available

  21. MCNICHOLAS DP, El-Taji O, Siddiqui Z, Hanchanale V, et al
    Systematic review comparing uretero-enteric stricture rates between open cystectomy with ileal conduit, robotic cystectomy with extra-corporeal ileal conduit and robotic cystectomy with intra corporeal ileal conduit formation.
    J Robot Surg. 2024;18:100.
    PubMed    
    Abstract available

  22. HU P, Dai HI, Bourdage J, Zhou D, et al
    Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
    Clin Transl Sci. 2024;17:e13730.
    PubMed    
    Abstract available

  23. ZHOU X, Xue F, Li T, Xue J, et al
    Exploration of potential biomarkers for early bladder cancer based on urine proteomics.
    Front Oncol. 2024;14:1309842.
    PubMed    
    Abstract available

  24. SHEN D, Kang S
    Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.
    Biol Direct. 2024;19:17.
    PubMed    
    Abstract available

  25. CHEN Q, Tan S, Long S, Wang K, et al
    Vagococcus fluvialis isolation from the urine of a bladder cancer patient: a case report.
    BMC Infect Dis. 2024;24:261.
    PubMed    
    Abstract available

  26. YEARY KHK, Yu H, Kuliszewski MG, Li Q, et al
    Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2024 Feb 26:1-9. doi: 10.6004/jnccn.2023.7086.
    PubMed    
    Abstract available

  27. URABE F
    Letter to the editor for the article "Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma".
    World J Urol. 2024;42:101.
    PubMed    


  28. KORNER SK, Dreyer T, Carus A, Dohn LH, et al
    DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
    Scand J Urol. 2024;59:39-46.
    PubMed    
    Abstract available

  29. BENDERSKA-SODER N, Ecke T, Kleinlein L, Roghmann F, et al
    Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
    Urol Oncol. 2024 Feb 24:S1078-1439(24)00041.
    PubMed    
    Abstract available

  30. LIU G, Jin K, Liu Z, Su X, et al
    Integration of CD4(+) T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.
    Cancer Sci. 2024 Feb 25. doi: 10.1111/cas.16119.
    PubMed    
    Abstract available

  31. PANG ZQ, Wang JS, Wang JF, Wang YX, et al
    JAM3 is a potential risk biomarker for predicting prognosis and immune cell infiltration by regulating epithelial-mesenchymal transition in bladder cancer.
    Biomol Biomed. 2024 Feb 23. doi: 10.17305/bb.2024.9979.
    PubMed    
    Abstract available

  32. FAN Z, Deng J, Wang Y, Fan X, et al
    Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection.
    Vaccines (Basel). 2024;12:150.
    PubMed    
    Abstract available

  33. CORVINO A, Basile L, Cocco G, Delli Pizzi A, et al
    Complications Subsequent to Urinary Tract Stent Placement: An Overview Focusing on the Imaging of Cancer Patients.
    Medicina (Kaunas). 2024;60:338.
    PubMed    
    Abstract available

  34. ALBERCA-DEL ARCO F, Prieto-Cuadra D, Santos-Perez de la Blanca R, Saez-Barranquero F, et al
    New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.
    Cancers (Basel). 2024;16:803.
    PubMed    
    Abstract available

  35. KRAVCHUK AP, Wolff I, Gilfrich C, Wirtz RM, et al
    Urine-Based Biomarker Test Uromonitor((R)) in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.
    Cancers (Basel). 2024;16:753.
    PubMed    
    Abstract available

  36. VUKOVIC M, Chamlati JM, Hennenlotter J, Todenhofer T, et al
    Interleukin-1beta/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer-An Exploratory Analysis of Clinical and Tumor Biological Significance.
    Int J Mol Sci. 2024;25:2447.
    PubMed    
    Abstract available

  37. TORRES-BUSTAMANTE MI, Vazquez-Urrutia JR, Solorzano-Ibarra F, Ortiz-Lazareno PC, et al
    The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer.
    Int J Mol Sci. 2024;25:2178.
    PubMed    
    Abstract available

  38. HE K, Meng X, Wang Y, Feng C, et al
    Progress of Multiparameter Magnetic Resonance Imaging in Bladder Cancer: A Comprehensive Literature Review.
    Diagnostics (Basel). 2024;14:442.
    PubMed    
    Abstract available

  39. XU C, Zhou J, Zhang X, Kang X, et al
    N(6)-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges.
    Cell Mol Biol Lett. 2024;29:28.
    PubMed    
    Abstract available

  40. LUO H, Wang Z
    Pan-cancer analysis reveals potential immunological and prognostic roles of COA6 in human cancers and preliminary exploration of COA6 in bladder cancer.
    Cell Signal. 2024;117:111111.
    PubMed    
    Abstract available

  41. MINATO A, Furubayashi N, Nagata Y, Tomoda T, et al
    Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
    Curr Oncol. 2024;31:862-871.
    PubMed    
    Abstract available

  42. ENDO Y, Akatsuka J, Takeda H, Hasegawa H, et al
    Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
    Curr Oncol. 2024;31:759-768.
    PubMed    
    Abstract available

  43. MORIA FA, Park CL, Eigl BJ, Macfarlane R, et al
    A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.
    Curr Oncol. 2024;31:704-722.
    PubMed    
    Abstract available

  44. CARDILLO TM, Zalath MB, Arrojo R, Sharkey RM, et al
    Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
    Oncotarget. 2024;15:144-158.
    PubMed    
    Abstract available

  45. PULIATTI S, Ferretti S, Penaranda NR, Eissa A, et al
    Applicability and feasibility of robot-assisted cystectomy and intracorporeal urinary diversion in a patient with right renal pelvic ectopia.
    Int Braz J Urol. 2024;50:227-228.
    PubMed    
    Abstract available

  46. BITTING RL, Tooze JA, Goodman M, Vile DC, et al
    Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
    Cancer Res Commun. 2024;4:530-539.
    PubMed    
    Abstract available

  47. STOLL AK, Koll FJ, Eckstein M, Reis H, et al
    [Histomolecular classification of urothelial carcinoma of the urinary bladder : From histological phenotype to genotype and back].
    Pathologie (Heidelb). 2024;45:106-114.
    PubMed    
    Abstract available

  48. OLDAN JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, et al
    PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
    PET Clin. 2024;19:197-206.
    PubMed    
    Abstract available

  49. HOFFMAN-CENSITS J, Grivas P, Powles T, Hawley J, et al
    The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Future Oncol. 2024;20:179-190.
    PubMed    
    Abstract available

  50. LIU G, Jin K, Liu Z, Su X, et al
    POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
    Cancer Med. 2024;13:e6962.
    PubMed    
    Abstract available

  51. NAGATA Y, Goto T, Teramoto Y, Matsukawa T, et al
    Mineralocorticoid receptor signaling inhibits bladder cancer progression.
    Am J Cancer Res. 2024;14:696-708.
    PubMed    
    Abstract available

  52. WEI L, Wang SS, Huang ZG, He RQ, et al
    TM9SF1 promotes bladder cancer cell growth and infiltration.
    World J Clin Oncol. 2024;15:302-316.
    PubMed    
    Abstract available

  53. ZHOU SQ, Luo LX
    TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells.
    World J Clin Oncol. 2024;15:175-177.
    PubMed    
    Abstract available

  54. PENG Z, Zhuang J, Shen B
    The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.
    Microbiome Res Rep. 2023;3:5.
    PubMed    
    Abstract available

  55. DJATISOESANTO W, Azmi YA, Yatindra IBGTY
    The relationship between income, health insurance, and employment status as prognostic indicators of bladder cancer: a survival analysis.
    Arch Ital Urol Androl. 2024 Mar 7:12305. doi: 10.4081/aiua.2024.12305.
    PubMed    
    Abstract available

  56. NOLTING J, Nitzsche R, Kiss B, Hakenberg OW, et al
    Prospective evaluation of sexual health following radical cystectomy due to bladder cancer.
    Sex Med. 2024;12:qfae005.
    PubMed    
    Abstract available

  57. OSHIRO H, Shimizu Y, Nakayasu R, Yamaguchi R, et al
    [Bladder Cancer Detected Incidentally by Cystoscopy before Radical Prostatectomy].
    Hinyokika Kiyo. 2024;70:39-43.
    PubMed    
    Abstract available

  58. NIEGISCH G
    Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    N Engl J Med. 2024;390:944-946.
    PubMed    


  59. POWLES T, Valderrama BP, Gupta S, Bedke J, et al
    Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    N Engl J Med. 2024;390:875-888.
    PubMed    
    Abstract available

  60. MAIORANO BA, Di Maio M, Cerbone L, Maiello E, et al
    Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    JAMA Netw Open. 2024;7:e241215.
    PubMed    
    Abstract available

  61. KONG YL, Wang HD, Gao M, Rong SZ, et al
    LncRNA XIST promotes bladder cancer progression by modulating miR-129-5p/TNFSF10 axis.
    Discov Oncol. 2024;15:65.
    PubMed    
    Abstract available

  62. HUANG Y, Liao C, Shen Z, Zou Y, et al
    A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.
    Front Immunol. 2024;15:1297542.
    PubMed    
    Abstract available

  63. HUANG XL, Sun Y, Wen P, Pan JC, et al
    The potential mechanism of ursolic acid in the treatment of bladder cancer based on network pharmacology and molecular docking.
    J Int Med Res. 2024;52:3000605241234006.
    PubMed    
    Abstract available

  64. WANG Q, Zhang R, He Y, Mao G, et al
    Taraxasterol enhanced bladder cancer cells radiosensitivity via inhibiting the COX-2/PGE2/JAK2/STAT3/MMP pathway.
    Int J Radiat Biol. 2024 Mar 5:1-11. doi: 10.1080/09553002.2024.2324475.
    PubMed    
    Abstract available

  65. ZHANG Q, Wang L, Yu L, Yu Q, et al
    Tectoridin inhibits the growth of bladder cancer by regulating PI3K/MAPK pathway through RAB27B.
    Mol Carcinog. 2024 Mar 5. doi: 10.1002/mc.23712.
    PubMed    
    Abstract available

  66. MITANI K, Tsuboi I, Tanaka G, Yosioka S, et al
    Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report.
    IJU Case Rep. 2023;7:127-130.
    PubMed    
    Abstract available

  67. CHEN YT, Tang QY, Zhang YX, Wang SZ, et al
    An Atlas of Dietary Intakes and Medication Uses on Risk of Bladder Cancer: A Wide-Angle Mendelian Randomization Analysis.
    Nutr Cancer. 2024 Mar 5:1-10. doi: 10.1080/01635581.2024.2324504.
    PubMed    
    Abstract available

  68. ABOU CHAKRA M, Moussa M, O'Donnell MA
    Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability.
    J Chemother. 2024 Mar 4:1-4. doi: 10.1080/1120009X.2024.2325765.
    PubMed    


  69. LIU Y, Zou SH, Gao X
    Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms.
    Genes Genomics. 2024 Mar 4. doi: 10.1007/s13258-024-01505.
    PubMed    
    Abstract available

  70. LI M, Nandurkar R, Toniolo J, Davis ID, et al
    A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity.
    World J Urol. 2024;42:115.
    PubMed    
    Abstract available

  71. XIONG Q, Liu T, Ying Y, Yu X, et al
    Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.
    Bioeng Transl Med. 2023;9:e10624.
    PubMed    
    Abstract available

  72. WEI H, Cheng X, Wang G, Li Z, et al
    Causal association of smoking, blood lipids, and bladder cancer: Insights from a multivariable and mediation mendelian randomization investigation.
    J Cancer. 2024;15:1929-1939.
    PubMed    
    Abstract available

  73. CHEN J, Fan S, Guo J, Yang J, et al
    Discovery of anticancer function of Febrifugine: Inhibition of cell proliferation, induction of apoptosis and suppression steroid synthesis in bladder cancer cells.
    Toxicol Appl Pharmacol. 2024;484:116878.
    PubMed    
    Abstract available

  74. SZCZESNIEWSKI JJ, Marquez-Sanchez MT, Padilla-Fernandez B, Llanes-Gonzalez L, et al
    Recurrent Bacteriuria as a Prognosis Marker in the Adjuvant Treatment of Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102048.
    PubMed    
    Abstract available

  75. HAO S, Shen L, Liu P, Yong Q, et al
    Development of a prognostic model for muscle-invasive bladder cancer using glutamine metabolism.
    Comput Biol Med. 2024;171:108223.
    PubMed    
    Abstract available

  76. LI B, Jin K, Liu Z, Su X, et al
    Integrating molecular subtype and CD8(+) T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2024;73:66.
    PubMed    
    Abstract available

  77. FU Y, Sun S, Shi D, Bi J, et al
    Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.
    J Cell Mol Med. 2024;28:e18155.
    PubMed    
    Abstract available

  78. ODURO MS
    A Bayesian Bernoulli-Exponential joint model for binary longitudinal outcomes and informative time with applications to bladder cancer recurrence data.
    BMC Med Res Methodol. 2024;24:54.
    PubMed    
    Abstract available

  79. COOKE I, Abou Heidar N, Mahmood AW, Ahmad A, et al
    The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.
    Urol Oncol. 2024 Feb 29:S1078-1439(24)00002.
    PubMed    
    Abstract available

  80. CHEN KC, Dhar T, Chen CR, Chen CY, et al
    Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity.
    Biochim Biophys Acta Mol Basis Dis. 2024 Feb 28:167106.
    PubMed    
    Abstract available

  81. QI F, Bao Q, Hu P, Guo Y, et al
    Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy.
    Biomaterials. 2024;307:122514.
    PubMed    
    Abstract available

  82. BASILE G, Gallioli A, Martini A, Verri P, et al
    Oncologic surveillance intensity after endoscopic treatment of upper tract urothelial carcinoma.
    Minerva Urol Nephrol. 2024;76:88-96.
    PubMed    
    Abstract available

  83. OKUDA Y, Kato T, Fujita K, Fushimi H, et al
    Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Cancer Genomics Proteomics. 2024;21:137-143.
    PubMed    
    Abstract available

  84. FAVERO PRIETTO DOS SANTOS J, Ghezzi CLA, Pedrollo IM, Cruz IR, et al
    Practical Guide to VI-RADS: MRI Protocols, Lesion Characterization, and Pitfalls.
    Radiographics. 2024;44:e230149.
    PubMed    
    Abstract available

  85. HOEGGER MJ
    Invited Commentary: VI-RADS and Routing Patient Care at the Muscularis Propria.
    Radiographics. 2024;44:e230234.
    PubMed    


  86. KAPAGANTI VK, Purkait S, Nayak P, Biswas D, et al
    Diminution of Primary Cilia in the Stromal Cells at the Tumor-stromal Interface Correlates With an Aggressive Tumor Biology in the Urothelial Carcinoma of the Urinary Bladder.
    Appl Immunohistochem Mol Morphol. 2024;32:130-136.
    PubMed    
    Abstract available

  87. BARCENA PGQ, Aprikian AG, Dragomir A
    Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
    Cancer Med. 2024;13:e6922.
    PubMed    
    Abstract available

  88. ZHANG H, Lee S, Muthakana RR, Lu B, et al
    Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
    Cancer Immunol Res. 2024;12:287-295.
    PubMed    
    Abstract available

  89. LI JJX, Ng JKM, Tang CY, Chan BCH, et al
    Urine cytology in the detection of renal cell carcinomas - a territory-wide multi-institutional retrospective review of more than 2 decades.
    Cancer Cytopathol. 2024;132:186-192.
    PubMed    
    Abstract available

  90. DASON S, Lee CT
    Paradigm Shifting Research: Key Studies in Urologic Oncology.
    Ann Surg Oncol. 2024;31:2529-2537.
    PubMed    
    Abstract available

  91. MUQUITH M, Hsiehchen D
    Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.
    Oncologist. 2024;29:219-226.
    PubMed    
    Abstract available

  92. MILOJEVIC B, Janicic A, Grozdic Milojevic I, Grubor N, et al
    Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2024;31:2538-2544.
    PubMed    
    Abstract available

  93. KANNAN N, Gochhait D, Ramanitharan M, Siddaraju N, et al
    A comparison between conventional and the Paris systems of reporting urinary cytopathology with a literature update.
    Diagn Cytopathol. 2024;52:187-199.
    PubMed    
    Abstract available

  94. XU Q, Li T, Lin J, Wu X, et al
    Label-free screening of common urinary system tumors from blood plasma based on surface-enhanced Raman spectroscopy.
    Photodiagnosis Photodyn Ther. 2024;45:103900.
    PubMed    
    Abstract available

  95. ALHAMAR M, Al-Ahmadie HA, Feratovic R, Lin O, et al
    Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience.
    Cancer Cytopathol. 2024;132:144-151.
    PubMed    
    Abstract available

  96. LORIOT Y, O'Hagan A, Siefker-Radtke AO
    Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Future Oncol. 2024;20:231-243.
    PubMed    
    Abstract available

  97. GUPTA S, Costantino H, Ike C, Gupta S, et al
    Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
    Oncologist. 2024;29:244-253.
    PubMed    
    Abstract available

  98. RAICES FRANCISCO N, Suarez Gil R, Ayuso Garcia B, Romay Lema E, et al
    BCGitis with aortoiliac aneurysm involvement: Report of two cases and review of the literature.
    Enferm Infecc Microbiol Clin (Engl Ed). 2024;42:152-157.
    PubMed    
    Abstract available


  99. A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation: Erratum.
    Medicine (Baltimore). 2024;103:e37547.
    PubMed    


  100. WANG W, Chen Y, Gu J
    Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: A comparative study.
    Medicine (Baltimore). 2024;103:e36871.
    PubMed    
    Abstract available

  101. LI S, Wang J, Zhang Z, Wu Y, et al
    Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation.
    Medicine (Baltimore). 2024;103:e37492.
    PubMed    
    Abstract available

  102. XIE L, Liang S, Jiwa H, Zhang L, et al
    Securinine inhibits the tumor growth of human bladder cancer cells by suppressing Wnt/beta-catenin signaling pathway and activating p38 and JNK signaling pathways.
    Biochem Pharmacol. 2024 Mar 12:116125. doi: 10.1016/j.bcp.2024.116125.
    PubMed    
    Abstract available

  103. BRUNELLI M, Gobbo S, Malpeli G, Sirgiovanni G, et al
    TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
    Pathologica. 2024;116:55-61.
    PubMed    
    Abstract available

  104. LI H, Bao X, Xiao Y, Yin H, et al
    Identification and verification of anoikis-related gene markers to predict the prognosis of patients with bladder cancer and assist in the diagnosis and treatment of bladder cancer.
    Transl Cancer Res. 2024;13:579-593.
    PubMed    
    Abstract available

  105. YIN JJ, Song YL, Guo YF, Dai YH, et al
    Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.
    Front Genet. 2024;15:1333931.
    PubMed    
    Abstract available

  106. FENG S, Zhou D, Li Y, Yuan R, et al
    Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.
    Front Oncol. 2024;14:1276526.
    PubMed    
    Abstract available

  107. MENG W, Li N, Chen B, Zhang H, et al
    Reliable prognostic definition and immunotherapy response prediction in bladder cancer, based on a novel aging-associated 5-gene signature model.
    Transl Androl Urol. 2024;13:193-208.
    PubMed    
    Abstract available

  108. JALALIZADEH M, Reis LO
    Understanding bladder cancer by genome-wide association studies.
    Transl Androl Urol. 2024;13:363-365.
    PubMed    


  109. LAN T, Ran S, Gao M, Li W, et al
    A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?
    Transl Androl Urol. 2024;13:293-307.
    PubMed    
    Abstract available

  110. SHAH S, Ince J, Kockelbergh R
    Patient experience of bladder cancer: A data linkage study.
    BJUI Compass. 2024;5:382-388.
    PubMed    
    Abstract available

  111. WANG R, Xu F, Yang Z, Cao J, et al
    The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation.
    BMC Urol. 2024;24:59.
    PubMed    
    Abstract available

  112. REIKE MJ, de Jong JJ, Bismar TA, Boorjian SA, et al
    Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
    Urol Oncol. 2024 Mar 12:S1078-1439(24)00043.
    PubMed    
    Abstract available

  113. XU VE, Antar RM, Bertozzi L, Drouaud A, et al
    Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases.
    Urol Oncol. 2024 Mar 12:S1078-1439(24)00337.
    PubMed    
    Abstract available

  114. WANG P, Wei X, Shen L, Xu K, et al
    Amplification-Free Analysis of Bladder Cancer MicroRNAs on Wrinkled Silica Nanoparticles with DNA-Functionalized Quantum Dots.
    Anal Chem. 2024 Mar 13. doi: 10.1021/acs.analchem.3c05204.
    PubMed    
    Abstract available

  115. PFISTER C, Harter V, Allory Y, Culine S, et al
    Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?
    World J Urol. 2024;42:140.
    PubMed    


  116. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection.
    Histopathology. 2024 Mar 13. doi: 10.1111/his.15177.
    PubMed    
    Abstract available

  117. LI F, Wang P, Ye J, Xie G, et al
    Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.
    Front Oncol. 2024;14:1303918.
    PubMed    
    Abstract available

  118. XIE H, Rutz J, Maxeiner S, Grein T, et al
    Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro.
    Nutrients. 2024;16:623.
    PubMed    
    Abstract available

  119. DU C, Waltzer WC, Wilusz JE, Spaliviero M, et al
    Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.
    Cancers (Basel). 2024;16:978.
    PubMed    
    Abstract available

  120. STANKOWSKA W, Sarkisyan D, Bruhn-Olszewska B, Duzowska K, et al
    Tumor Predisposing Post-Zygotic Chromosomal Alterations in Bladder Cancer-Insights from Histologically Normal Urothelium.
    Cancers (Basel). 2024;16:961.
    PubMed    
    Abstract available

  121. CHANG PH, Chen HY, Chang YS, Su PJ, et al
    Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.
    Cancers (Basel). 2024;16:894.
    PubMed    
    Abstract available

  122. JIANG YH, Liu YS, Wei YC, Jhang JF, et al
    Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.
    Diagnostics (Basel). 2024;14:468.
    PubMed    
    Abstract available

  123. LUO C, Luo S, Wusimanjiang W, Wang Z, et al
    Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
    Clin Transl Oncol. 2024 Mar 12. doi: 10.1007/s12094-024-03400.
    PubMed    
    Abstract available

  124. FAN L, Wang J, Zhang Z, Zuo Z, et al
    Identification of RNA methylation-related lncRNAs for prognostic assessment and immunotherapy in bladder cancer-based on single cell/Bulk RNA sequencing data.
    Funct Integr Genomics. 2024;24:56.
    PubMed    
    Abstract available

  125. SEGATTO NV, Simoes LD, Bender CB, Sousa FS, et al
    Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro.
    Front Oncol. 2024;14:1323422.
    PubMed    
    Abstract available

  126. TONG Z, Zhao Y, Bai S, Ebner B, et al
    The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.
    Cancer Commun (Lond). 2024 Mar 11. doi: 10.1002/cac2.12532.
    PubMed    


  127. SUN H, Gao F, Liu Y, Shao J, et al
    Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis.
    BMC Urol. 2024;24:57.
    PubMed    
    Abstract available

  128. ZHANG L, Shi X, Zhang L, Mi Y, et al
    A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
    Cell Death Dis. 2024;15:204.
    PubMed    
    Abstract available

  129. FLURY-SUTTER S, Heuzeroth F, Arbelaez E, Bubendorf L, et al
    Efficacy and tolerability of bacillus Calmette-Guerin strain Russia for the treatment of non-muscle-invasive bladder cancer: Analysis of a prospective registry.
    Can Urol Assoc J. 2024 Mar 1. doi: 10.5489/cuaj.8552.
    PubMed    
    Abstract available

  130. ENLUND M, Hallberg H, Berglund A, Sherif A, et al
    Long-term survival after volatile or propofol general anesthesia for bladder cancer surgery: a retrospective national registry cohort study.
    Anesthesiology. 2024 Mar 11. doi: 10.1097/ALN.0000000000004969.
    PubMed    
    Abstract available

  131. ZHANG Y, Jia R, Wang X, Zhang Y, et al
    Targeted Delivery of Catalase and Photosensitizer Ce6 by a Tumor-Specific Aptamer Is Effective against Bladder Cancer In Vivo.
    Mol Pharm. 2024 Mar 11. doi: 10.1021/acs.molpharmaceut.3c01047.
    PubMed    
    Abstract available

  132. WANG P, Ning J, Chen W, Zou F, et al
    Comprehensive analysis indicated that NDE1 is a potential biomarker for pan-cancer and promotes bladder cancer progression.
    Cancer Med. 2024;13:e6931.
    PubMed    
    Abstract available

  133. WONG JYY, Fischer AH, Baris D, Beane Freeman LE, et al
    Urinary mutagenicity and bladder cancer risk in northern New England.
    Environ Mol Mutagen. 2024 Mar 11. doi: 10.1002/em.22588.
    PubMed    
    Abstract available

  134. YANG K, Qi ZX, Sun MX, Xie LP, et al
    Hyperoside induces cell cycle arrest and suppresses tumorigenesis in bladder cancer through the interaction of EGFR-Ras and Fas signaling pathways.
    Int J Med Sci. 2024;21:690-702.
    PubMed    
    Abstract available

  135. ZHUANG J, Zhang L, Zhang S, Zhang Z, et al
    Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1.
    Cell Biosci. 2024;14:32.
    PubMed    
    Abstract available

  136. LIN H, Fu L, Zhou X, Yu A, et al
    LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
    Cancer Lett. 2024 Mar 8:216807. doi: 10.1016/j.canlet.2024.216807.
    PubMed    
    Abstract available

  137. OTVAGIN VF, Krylova LV, Peskova NN, Kuzmina NS, et al
    A first-in-class beta-glucuronidase responsive conjugate for selective dual targeted and photodynamic therapy of bladder cancer.
    Eur J Med Chem. 2024;269:116283.
    PubMed    
    Abstract available

  138. SHI X, Pang S, Zhou J, Yan G, et al
    Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs.
    Mol Cancer. 2024;23:52.
    PubMed    
    Abstract available

  139. MITTAL K, Joshi M
    FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
    Med. 2024;5:176-178.
    PubMed    
    Abstract available

  140. HAGA N, Hashimoto S, Morimoto M
    [Multiple Pulmonary Metastases Seven Years After Transurethral Bladder Tumor Resection for Non-muscle Invasion Bladder Cancer:Report of a Case].
    Kyobu Geka. 2024;77:155-159.
    PubMed    
    Abstract available

  141. MEAGHER M, Morgan KM, Deshler L, Puri D, et al
    The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study.
    Clin Genitourin Cancer. 2024 Feb 15:102055. doi: 10.1016/j.clgc.2024.
    PubMed    
    Abstract available

  142. GUO L, Liu L, Liu Y, Yang T, et al
    Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
    BMJ Open. 2024;14:e080092.
    PubMed    
    Abstract available

  143. LI L, Fu S, Wang J, Lu J, et al
    SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.
    Biochem Pharmacol. 2024;222:116111.
    PubMed    
    Abstract available

  144. WOLF B, Jain RK
    Unraveling a hidden player in lymphovascular invasion in bladder cancer.
    Cancer Cell. 2024 Mar 6:S1535-6108(24)00051-5. doi: 10.1016/j.ccell.2024.
    PubMed    
    Abstract available

  145. SUSKI M
    Reconstruction of a large scalp defect secondary to a rare cutaneous metastasis from urothelial bladder carcinoma using intact fish skin xenografts.
    J Wound Care. 2024;33.
    PubMed    


  146. CHENG S, Li C, Liu L, Liu X, et al
    Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.
    Biol Direct. 2024;19:20.
    PubMed    
    Abstract available

  147. LI Q, Zhuo L, Zhang T
    Shame in patients undergoing ureterostomy: A cross-sectional survey.
    Int Wound J. 2024;21:e14793.
    PubMed    
    Abstract available

  148. WANG J, Xiao B, Ren S, Zeng D, et al
    A systematic review and meta-analysis of the anti-tumor effects of Paeoniae Radix Rubra in animal models.
    J Ethnopharmacol. 2024;326:117987.
    PubMed    
    Abstract available

  149. YANG W, Liu Z, Liu T
    Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Cell Signal. 2024;117:111107.
    PubMed    
    Abstract available

  150. ALEXANDER BH, Ryan A, Church TR, Kim H, et al
    Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers.
    Am J Ind Med. 2024;67:321-333.
    PubMed    
    Abstract available

  151. JIA L, Rood T, Kirkpatrick J, Sarode V, et al
    Utility of The Paris System (TPS) for upper urinary tract cytopathology: correlation with histology follow-up and UroVysion fluorescence in situ hybridization (FISH) analysis.
    J Am Soc Cytopathol. 2024;13:149-155.
    PubMed    
    Abstract available

  152. WOLDU S, Lotan Y
    Reply to Khurshid R. Ghani's letter to editor regarding the article "Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter evaluation of practice patterns and outcomes".
    Urol Oncol. 2024;42:36.
    PubMed    


  153. MCKENNA C, Poirier VJ, Oblak ML, Nykamp S, et al
    Reason for euthanasia in dogs with urothelial carcinoma treated with chemotherapy or radiation therapy or both: A retrospective observational study.
    J Vet Intern Med. 2024;38:1127-1134.
    PubMed    
    Abstract available

  154. NIZAM A, Rader RK, Tzeng A, Wei W, et al
    Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Clin Genitourin Cancer. 2024;22:368-379.
    PubMed    
    Abstract available

  155. JAGANMURUGAN R, Arora A, Chandankhede U, Prakash G, et al
    Prognostic Significance of Lymph Node Density in Pathological Node Positive Urothelial Carcinoma of the Bladder -Upfront Surgery and Post Neoadjuvant Chemotherapy Cohorts.
    Clin Genitourin Cancer. 2024;22:385-393.
    PubMed    
    Abstract available

  156. LYNCH C, Sweis RF, Modi P, Agarwal PK, et al
    Bladder-Preserving Trimodality Therapy With Capecitabine.
    Clin Genitourin Cancer. 2024;22:476-482.
    PubMed    
    Abstract available

  157. SOARES A, Bourlon MT, Wong A, Joshi A, et al
    Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
    Clin Genitourin Cancer. 2024;22:467-475.
    PubMed    
    Abstract available

  158. VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
    Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy.
    Clin Genitourin Cancer. 2024;22:336-346.
    PubMed    
    Abstract available

  159. TREPANIER G, Nykopp T, Rosebush-Mercier R, Gris T, et al
    Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guerin.
    Clin Genitourin Cancer. 2024;22:354-359.
    PubMed    
    Abstract available

  160. LIANG PI, Wei YC, Chen HD, Ma YC, et al
    TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma.
    Kaohsiung J Med Sci. 2024;40:269-279.
    PubMed    
    Abstract available

  161. FENOR DE LA MAZA MD, Villacampa G, Minana B, Barbas Bernardos G, et al
    First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies.
    Clin Genitourin Cancer. 2024;22:330-335.
    PubMed    
    Abstract available

  162. NAGAYAMA J, Yamamoto A, Naito Y, Kamikawa H, et al
    Efficacy of the Addition of Robot-assisted Radical Cystectomy with Extracorporeal Urinary Diversion after an Enhanced Recovery Protocol.
    Urol J. 2024;21:40-46.
    PubMed    
    Abstract available

  163. YE J, Wang X, Liao X, Chen Z, et al
    Survival impact of variant histology in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
    Urol Oncol. 2024;42:69.
    PubMed    
    Abstract available

  164. KITAHAMA K, Shigematsu Y, Amori G, Sugawara E, et al
    RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
    Am J Surg Pathol. 2024;48:458-464.
    PubMed    
    Abstract available

  165. KATAYAMA S, Iwata T, Kawada T, Okamoto Y, et al
    Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Urol Oncol. 2024;42:70.
    PubMed    
    Abstract available

  166. SHIPP C, Jindal T, Chou J, Friedlander TW, et al
    Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
    Clin Genitourin Cancer. 2024;22:315-321.
    PubMed    


  167. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
    Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
    Jpn J Clin Oncol. 2024;54:254-264.
    PubMed    
    Abstract available

  168. KOHADA Y, Goto K, Tasaka R, Nishida K, et al
    Prognostic Impact of the Modified 5-Item Frailty Index After Radical Nephroureterectomy in Patients With Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study.
    Clin Genitourin Cancer. 2024;22:322-329.
    PubMed    
    Abstract available

  169. KOU Z, Wang P, Jia D, Zhu H, et al
    Clinical analysis of small-cell carcinoma of the urinary bladder: A case report and review of literature.
    Asian J Surg. 2024;47:1602-1603.
    PubMed    


  170. MIYAKE M, Nishimura N, Oda Y, Miyamoto T, et al
    Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
    Jpn J Clin Oncol. 2024;54:329-338.
    PubMed    
    Abstract available

  171. STANGL FP, Buehler OD, Wuethrich PY, Furrer MA, et al
    Sex Does Not Affect Survival: A Propensity Score-Matched Comparison in a Homogenous Contemporary Radical Cystectomy Cohort.
    Clin Genitourin Cancer. 2024;22:171-180.
    PubMed    
    Abstract available

  172. CAMPBELL RA, Khanna A, Boorjian SA, Knorr J, et al
    Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
    Clin Genitourin Cancer. 2024;22:157-163.
    PubMed    
    Abstract available

  173. HOIMES CJ, Flaig TW, Milowsky MI, Friedlander TW, et al
    A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Future Oncol. 2024;20:351-360.
    PubMed    
    Abstract available

  174. GUO Q, Jin L, Zhang T, Gao R, et al
    Literature analysis of cutaneous adverse reactions induced by tislelizumab.
    Cutan Ocul Toxicol. 2024;43:52-57.
    PubMed    
    Abstract available

  175. FERRO M, Chiujdea S, Vartolomei MD, Bove P, et al
    Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:27-37.
    PubMed    
    Abstract available

  176. ARITA Y, Kwee TC, Woo S, Shigeta K, et al
    Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System.
    Eur Urol Focus. 2024;10:131-138.
    PubMed    
    Abstract available

  177. CAI L, Yu R, Liu P, Zhuang J, et al
    A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk.
    J Magn Reson Imaging. 2023 Aug 21. doi: 10.1002/jmri.28924.
    PubMed    
    Abstract available

  178. TAKEUCHI M
    Editorial for "A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk".
    J Magn Reson Imaging. 2023 Aug 9. doi: 10.1002/jmri.28922.
    PubMed    


  179. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
    Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Ren
    Eur Urol Focus. 2024;10:169-181.
    PubMed    
    Abstract available

  180. HASHEM M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, et al
    Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.
    Noncoding RNA Res. 2024;9:560-582.
    PubMed    
    Abstract available

  181. BERGMAN DR, Wang Y, Trujillo E, Fernald AA, et al
    Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
    Front Immunol. 2024;15:1358019.
    PubMed    
    Abstract available

  182. DU G, Jiang Z, Qu W, Zhang J, et al
    Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report.
    Heliyon. 2024;10:e27685.
    PubMed    
    Abstract available

  183. TAO T, Chen Y, Shang Y, He J, et al
    SMMF: a self-attention-based multi-parametric MRI feature fusion framework for the diagnosis of bladder cancer grading.
    Front Oncol. 2024;14:1337186.
    PubMed    
    Abstract available

  184. LI L, Jiang P, Hu W, Zou F, et al
    AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    J Transl Med. 2024;22:295.
    PubMed    
    Abstract available

  185. MOADAB A, Valizadeh MR, Nazari A, Khorramdelazad H, et al
    Association of interleukin-17A and chemokine/vascular endothelial growth factor-induced angiogenesis in newly diagnosed patients with bladder cancer.
    BMC Immunol. 2024;25:20.
    PubMed    
    Abstract available

  186. MURAKAMI T, Minami K, Harabayashi T, Maruyama S, et al
    Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.
    Sci Rep. 2024;14:6801.
    PubMed    
    Abstract available

  187. BENBASSAT J
    Estimates of the lead time in screening for bladder cancer.
    Urol Oncol. 2024;42:110-114.
    PubMed    
    Abstract available

  188. NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
    Treatment patterns and prognosis in patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    World J Urol. 2024;42:185.
    PubMed    
    Abstract available

  189. YE J, Zheng L, Chen Z, Wang Q, et al
    Serum alpha-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy.
    BMC Urol. 2024;24:62.
    PubMed    
    Abstract available

  190. IKUMA S, Akatsuka J, Takeda H, Endo Y, et al
    Determining the clinicopathological significance of the VI-RADS >==4 group: a retrospective study.
    BMC Urol. 2024;24:63.
    PubMed    
    Abstract available

  191. CZECH AK, Gronostaj K, Frydrych J, Polok K, et al
    The assessment of bladder cancer resectability with bimanual palpation: A prospective study in laparoscopy and open cystectomy patients.
    Urol Oncol. 2024 Mar 19:S1078-1439(24)00335.
    PubMed    
    Abstract available

  192. BAARD J, Cormio L, Dasgupta R, Maruzzi D, et al
    Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study.
    World J Urol. 2024;42:177.
    PubMed    
    Abstract available

  193. KLEIN C, Brunelle S, Illy M, De Luca V, et al
    Multiparametric Magnetic Resonance Imaging in the follow-up of non-muscle-invasive bladder tumors after intravesical instillations: a promising tool.
    World J Urol. 2024;42:178.
    PubMed    
    Abstract available

  194. ALHAJAHJEH A, Abdulelah AA, Hmeidan M, Kakish D, et al
    Gender inequality in genitourinary malignancies clinical trials leadership.
    World J Urol. 2024;42:174.
    PubMed    
    Abstract available

  195. SKOWRONSKI M, Halicki P, Halicka A
    Disseminated BCGitis after intravesical Bacillus Calmette-Guerin therapy in a patient with bladder cancer.
    Pol Arch Intern Med. 2024 Mar 20:16710. doi: 10.20452/pamw.16710.
    PubMed    


  196. WANG Y, Wang J, Zhang L, He J, et al
    Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.
    J Cell Mol Med. 2024;28:1-20.
    PubMed    
    Abstract available

  197. DONG C, Hui P, Wu Z, Li J, et al
    CircRNA LOC729852 promotes bladder cancer progression by regulating macrophage polarization and recruitment via the miR-769-5p/IL-10 axis.
    J Cell Mol Med. 2024;28:e18225.
    PubMed    
    Abstract available

  198. YANG J, Xiang H, Cheng M, Jiang X, et al
    microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2.
    Neoplasma. 2024;71:60-69.
    PubMed    
    Abstract available

  199. TOUALA-CHAILA Z, Abderrahmane RK, Kerroumi S, Yousfi MJ, et al
    Association study of the polymorphisms rs2228611 of the DNMT1 gene and rs1569686 of the DNMT3B gene with bladder cancer development in a sample of the Algerian population.
    Mol Biol Res Commun. 2024;13:65-72.
    PubMed    
    Abstract available

  200. LIU F, Li J, Zhou B, Shen Y, et al
    The Role of Emodin in the Treatment of Bladder Cancer based on Network Pharmacology and Experimental Verification.
    Comb Chem High Throughput Screen. 2024.
    PubMed    
    Abstract available

  201. ANGELONI M, van Doeveren T, Lindner S, Volland P, et al
    A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
    J Pathol Clin Res. 2024;10:e12369.
    PubMed    
    Abstract available

  202. WU J, Lin Y, Yang K, Liu X, et al
    Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
    Mol Cancer. 2024;23:57.
    PubMed    
    Abstract available

  203. LV L, Wei Q, Zhang J, Dong Y, et al
    IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
    Cell Mol Biol Lett. 2024;29:39.
    PubMed    
    Abstract available

  204. CHAI JL, Roller LA, Liu X, Lan Z, et al
    Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis.
    Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04245.
    PubMed    
    Abstract available

  205. LIANG JP, Yin L, Gao LK, Yin L, et al
    Contrast-enhanced CT in the differential diagnosis of bladder cancer and paraganglioma.
    Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04217.
    PubMed    
    Abstract available

  206. MOUSSA M, Abou Chakra M, Shore ND, Papatsoris A, et al
    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
    Arch Ital Urol Androl. 2024 Mar 19:12244. doi: 10.4081/aiua.2024.12244.
    PubMed    
    Abstract available

  207. LEONARDI R, Ambrosini F, Cafarelli A, Calarco A, et al
    Office-based management of non-muscle invasive bladder cancer (NMIBC): a position paper on current state of the art and future perspectives.
    Arch Ital Urol Androl. 2024 Mar 19:12404. doi: 10.4081/aiua.2024.12404.
    PubMed    
    Abstract available

  208. CHEN S, Zhang S, Fan W, Sun W, et al
    [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
    Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:210-216.
    PubMed    
    Abstract available

  209. WANG B, Fan X, Wang L, Wei X, et al
    The RNA-binding protein sorbin and SH3 domain-containing 2 are transcriptionally regulated by specificity protein 1 and function as tumor suppressors in bladder cancer by stabilizing tissue factor pathway inhibitor.
    Mol Carcinog. 2024 Mar 19. doi: 10.1002/mc.23717.
    PubMed    
    Abstract available

  210. KIMURA T, Okita Y, Nagumo Y, Chin JM, et al
    Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif.
    Pathol Int. 2024 Mar 19. doi: 10.1111/pin.13419.
    PubMed    
    Abstract available

  211. WANG KY, Wang KJ, Shen LL, Wang XH, et al
    The down-regulation of GADD45B leads to a conversion of cellular oxidative phosphorylation to glycolysis and promotes the progression of bladder cancer.
    Heliyon. 2024;10:e27427.
    PubMed    
    Abstract available

  212. CHEN Y, Shi K, Fu X, Guo H, et al
    Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2024;14:1336375.
    PubMed    
    Abstract available

  213. OHARA K, Rendeiro AF, Bhinder B, Eng KW, et al
    The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
    Nat Commun. 2024;15:2009.
    PubMed    
    Abstract available

  214. QIN X, Wang H, Xu W, Zheng B, et al
    A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer.
    J Med Chem. 2024 Mar 18. doi: 10.1021/acs.jmedchem.4c00060.
    PubMed    
    Abstract available

  215. SUN X, Liu C, Zhang C, Zhang Z, et al
    Nomogram for predicting postoperative ileus after radical cystectomy and urinary diversion: a retrospective single-center study.
    Ann Med. 2024;56:2329125.
    PubMed    
    Abstract available

  216. WANG JF, Gong YQ, He YH, Ying WW, et al
    Author Correction: High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer.
    Eur Rev Med Pharmacol Sci. 2024;28:1640.
    PubMed    
    Abstract available

  217. WU H, Jin H, Cai Y
    Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder cancer.
    J Biomol Struct Dyn. 2024 Mar 18:1-10. doi: 10.1080/07391102.2024.2329799.
    PubMed    
    Abstract available

  218. WANG Y, Wang J, Liu Y, Wang X, et al
    Multidimensional pan-cancer analysis of HSPA5 and its validation in the prognostic value of bladder cancer.
    Heliyon. 2024;10:e27184.
    PubMed    
    Abstract available

  219. HAN H, Oh TJ, Heo JE, Lee J, et al
    Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2024;62:99-106.
    PubMed    
    Abstract available

  220. DE JONG FC, Ifle IG, van der Made AC, Kooper D, et al
    A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
    Eur Urol Open Sci. 2024;62:131-139.
    PubMed    
    Abstract available

  221. PAVAN N, Scaggiante B
    Editorial: Liquid biopsy in the detection and prediction of outcomes in bladder cancer.
    Front Oncol. 2024;14:1391466.
    PubMed    


  222. YAO R, Ai B, Wang Z, Shen B, et al
    Uncovering Microbial Composition of the Tissue Microenvironment in Bladder Cancer using RNA Sequencing Data.
    J Cancer. 2024;15:2431-2441.
    PubMed    
    Abstract available

  223. KOMORI K, Koyama K, Shimizu K, Kanemoto R, et al
    [A Case of Colon Metastasis after Surgery for Left Renal Pelvis Cancer].
    Gan To Kagaku Ryoho. 2024;51:340-342.
    PubMed    
    Abstract available

  224. ARABYAN G, Hambartzhumian R, Lim A, Quizon M, et al
    Unusual Urothelial Tumors and Refractory Uremia Due to Balkan Endemic Nephropathy: A Case Report.
    J Investig Med High Impact Case Rep. 2024;12:23247096241238529.
    PubMed    
    Abstract available

  225. WEI T, Yuan P
    [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
    Zhonghua Zhong Liu Za Zhi. 2024;46:211-220.
    PubMed    
    Abstract available

  226. LIU Y, Zhang K, Yang X
    CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis.
    J Egypt Natl Canc Inst. 2024;36:8.
    PubMed    
    Abstract available

  227. WU J, Gao F, Meng R, Li H, et al
    Single-cell and multi-omics analyses highlight cancer-associated fibroblasts-induced immune evasion and epithelial mesenchymal transition for smoking bladder cancer.
    Toxicology. 2024;504:153782.
    PubMed    
    Abstract available

  228. PAZIR Y, Esmeray A, Gelmis M, Caglar U, et al
    Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
    Urol J. 2024 Mar 17. doi: 10.22037/uj.v20i.7854.
    PubMed    
    Abstract available

  229. ROSENBAUM CM, Filmar S, Gross AJ, Jobst N, et al
    The influence of socioeconomic status and gender on incidence and survival in bladder cancer: a longitudinal study based on the Hamburg Cancer Registry.
    World J Urol. 2024;42:166.
    PubMed    
    Abstract available

  230. VAN DEN BRANDT PA
    Diabetes and the risk of bladder cancer subtypes in men and women: results from the Netherlands Cohort Study.
    Eur J Epidemiol. 2024 Mar 16. doi: 10.1007/s10654-024-01100.
    PubMed    
    Abstract available

  231. CEASAR RC, Ladi-Seyedian SS, Escobar D, Han J, et al
    "I think my vagina is still there?": Women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study.
    J Sex Med. 2024 Mar 15:qdae025. doi: 10.1093.
    PubMed    
    Abstract available

  232. WANG C, Yang X
    CircRAPGEF5 sponges miR-582-3p and targets KIF3A to regulate bladder cancer cell proliferation, migration and invasion.
    Int Immunopharmacol. 2024;131:111613.
    PubMed    
    Abstract available

  233. PYRGIDIS N, Schulz GB, Volz Y, Ebner B, et al
    The impact of perioperative risk factors on long-term survival after radical cystectomy: a prospective, high-volume cohort study.
    World J Urol. 2024;42:164.
    PubMed    
    Abstract available

  234. EMINAGA O, Lee TJ, La V, Breil B, et al
    Electronic Documentation of Intraoperative Observation of Cystoscopic Procedures Using the cMDX Information System.
    JCO Clin Cancer Inform. 2024;8:e2300114.
    PubMed    
    Abstract available

  235. KEHL KL, Lavery JA, Brown S, Fuchs H, et al
    Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
    JCO Precis Oncol. 2024;8:e2300489.
    PubMed    
    Abstract available

  236. SUARTZ CV, Cordeiro MD, Botelho LAA, Gallucci FP, et al
    Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score.
    World J Urol. 2024;42:155.
    PubMed    
    Abstract available

  237. DE CARLO A, Tosca EM, Fantozzi M, Magni P, et al
    Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
    Clin Pharmacol Ther. 2024;115:825-838.
    PubMed    
    Abstract available

  238. YU TW, Yamamoto H, Morita S, Fukushima R, et al
    Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.
    J Vet Med Sci. 2024;86:317-321.
    PubMed    
    Abstract available

  239. WU KY, Cheong IS, Lai JN, Hu CY, et al
    Risk of secondary primary malignancies in survivors of upper tract urothelial carcinoma: A nationwide population-based analysis.
    Cancer Epidemiol. 2024;89:102536.
    PubMed    
    Abstract available

  240. CRITCHLOW S, Bullement A, Crabb S, Jones R, et al
    Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Future Oncol. 2024;20:459-470.
    PubMed    
    Abstract available

  241. YU SH, Wang CY, Wang SS, Li JR, et al
    Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
    Anticancer Res. 2024;44:1299-1307.
    PubMed    
    Abstract available

  242. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    PubMed    
    Abstract available

  243. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
    A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
    PubMed    
    Abstract available

  244. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
    Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
    PubMed    
    Abstract available

  245. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
    The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
    PubMed    
    Abstract available

  246. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
    The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
    PubMed    
    Abstract available

  247. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
    Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
    BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
    PubMed    
    Abstract available

  248. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
    Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
    BJU Int. 2024;133:474-479.
    PubMed    
    Abstract available

  249. OUYANG Y, Zhong W, Xu P, Wang B, et al
    Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.
    Br J Cancer. 2024;130:880-891.
    PubMed    
    Abstract available

  250. JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
    Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
    Br J Cancer. 2024;130:897-907.
    PubMed    
    Abstract available

  251. HOSNI S, Kilian V, Klumper N, Gabbia D, et al
    Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Cancer Res. 2024;84:725-740.
    PubMed    
    Abstract available

  252. CALLERIS G, von Deimling M, Kesch C, Soria F, et al
    Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
    Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
    PubMed    
    Abstract available

  253. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
    Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    Abstract available

  254. GUPTA S, Necchi A
    LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
    Eur Urol. 2024;85:239-241.
    PubMed    


  255. HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
    Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
    Eur Urol. 2024;85:283-292.
    PubMed    
    Abstract available

  256. MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
    Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Eur Urol. 2024;85:229-238.
    PubMed    
    Abstract available

  257. HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
    Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
    Eur Urol. 2024;85:309-312.
    PubMed    


  258. CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
    Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
    Eur Urol. 2024;85:293-300.
    PubMed    
    Abstract available

  259. ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
    Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
    Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
    PubMed    


  260. LIEDBERG F, Bobjer J
    Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
    Eur Urol. 2024;85:392.
    PubMed    


  261. LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
    The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
    Eur Urol. 2024;85:317-319.
    PubMed    
    Abstract available

  262. DAHM P, Ergun O, Sathianathen N
    Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
    Eur Urol. 2024;85:e116.
    PubMed    


  263. PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
    Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
    Eur Urol. 2024;85:348-360.
    PubMed    
    Abstract available

  264. COX A, Klumper N, Stein J, Sikic D, et al
    Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
    Eur Urol. 2024;85:328-332.
    PubMed    
    Abstract available

  265. ATALLAH A, Grossman A, Nauman RW, Pare JF, et al
    Systemic versus localized Bacillus Calmette Guerin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Int J Cancer. 2024 Mar 14. doi: 10.1002/ijc.34897.
    PubMed    
    Abstract available

  266. XU M, Gu M, Zhou J, Da J, et al
    [Retracted] Interaction of YAP1 and mTOR promotes bladder cancer progression.
    Int J Oncol. 2024;64:50.
    PubMed    
    Abstract available

  267. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    PubMed    
    Abstract available

  268. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    PubMed    
    Abstract available

  269. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    PubMed    
    Abstract available

  270. LI B, Lin Y, Yang Y, Wang Z, et al
    Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Int Urol Nephrol. 2024;56:1243-1251.
    PubMed    
    Abstract available

  271. JAKUS D, Solic I, Borovac JA, Situm M, et al
    The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
    Int Urol Nephrol. 2024;56:1335-1341.
    PubMed    
    Abstract available

  272. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    PubMed    
    Abstract available

  273. DUAN H, Deng Z, Zou J, Zhang G, et al
    The efficacy and safety of Hyperthermia intravesical chemotherapy in the treatment non-muscle invasive bladder cancer:A meta analysis.
    Urol Int. 2024 Mar 20. doi: 10.1159/000538373.
    PubMed    
    Abstract available

  274. LIBLIK K, Queen JC, Touma NJ
    Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences.
    Urology. 2024 Feb 29:S0090-4295(24)00129-8. doi: 10.1016/j.urology.2024.
    PubMed    


  275. LEPOR H, Wiegand L, Patel K, Du W, et al
    A Randomized Clinical Trial Evaluating Indigo Carmine as a Visualization Aid for Evaluating Ureteral Patency.
    Urology. 2024;184:105-111.
    PubMed    
    Abstract available

  276. WEISS K, Abimbola O, Miller K, Kim WY, et al
    Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.
    Urology. 2024;184:75-78.
    PubMed    
    Abstract available

  277. HUELSTER HL, Mason NT, Davaro F, Naqvi SMH, et al
    Cost-Utility of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy.
    Urology. 2024 Mar 9:S0090-4295(24)00126-2. doi: 10.1016/j.urology.2024.
    PubMed    
    Abstract available

  278. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    PubMed    
    Abstract available

  279. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;